^
    Back
    Association details:
    Biomarker:TLR4 overexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Am J Cancer Res
    Title:

    TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma

    Published date:
    03/21/2020
    Excerpt:
    ...patients bearing tumors with a higher expression of TLR4 which were more resistant to cetuximab therapy displayed a poorer overall survival (OS) rate as well as disease free survival (DFS) rate…
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Am J Cancer Res
    Title:

    TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma

    Published date:
    03/21/2020
    Excerpt:
    Compared with control animals, TLR4 overexpressed CAL27 cells grew faster and were more resistant to cetuximab therapy…